You are currently viewing a new version of our website. To view the old version click .

Combining Ultrasound and Microbubbles/Nanobubbles for Enhancing the Effects of Cancer Therapies

This special issue belongs to the section “Nanomedicine and Nanotechnology“.

Special Issue Information

Dear Colleagues,

At present, there are different types of treatments for cancer. Patients receive adjuvant therapies based on their cancer type. The combined side effects of these therapies can sometimes be detrimental; therefore, novel methods that can selectively increase the effectiveness of these therapies without add-on toxicity are of utmost importance. In recent years, ultrasound-stimulated microbubbles/nanobubbles have widely been explored for their non-invasive nature and the potential to enhance the effects of existing cancer therapies, including radiation therapy, chemotherapy, and immunotherapy. Microbubbles/nanobubbles, when exposed to ultrasound waves, undergo several phenomena, such as expansion, compression, and even collision, facilitating several bioeffects. Several studies suggest that ultrasound and microbubbles/nanobubbles, when combined with cancer therapies, can lead to an additive or synergistic tumor response. After marking its success in preclinical studies, ultrasound-stimulated microbubbles/nanobubbles combined with cancer therapies are underway to demonstrate its impact on early-stage clinical trials. 

This Special Issue aims to cover the latest findings of tumor enhancement using ultrasound-stimulated microbubbles/nanobubbles and existing cancer therapies.

Dr. Yi-Ju Ho
Dr. Deepa Sharma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ultrasound
  • immunotherapy
  • radiation therapy
  • chemotherapy
  • micro/nano-bubble
  • cancer therapeutics
  • drug delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Pharmaceutics - ISSN 1999-4923